# US 2013/0281384 A1 · Larazotide acetate compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0281384 A1
- Document ID: US20130281384A1
- Status: Published application
- Kind: A1
- Application number: 13/832,820
- Filed: 2013-03-15
- Published: 2013-10-24
- Earliest claimed: 2007-11-21
- Assignees: Alba Therapeutics Corporation
- Inventors: Roland Callens; Georges Blondeel; Thierry Delplanche
- Web page: https://patentgrep.com/patent/US20130281384A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07C 53/10: Salts thereof
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties.

## Claims

### Claim 1

A crystalline salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), wherein the salt of the peptide is selected from hydrochloride or acetate.

### Claim 2 (depends on 1)

The crystalline salt according to claim 1, wherein the salt of the peptide is acetate.

### Claim 3 (depends on 2)

The crystalline salt according to claim 2, wherein the acetate is present at a concentration of less than 50 mole %/mole of peptide.

### Claim 4 (depends on 2)

The crystalline salt according to claim 2, wherein the acetate is present at a concentration of from 20 to 30 mole %/mole of peptide.

### Claim 5 (depends on 1)

The crystalline salt according to claim 1, wherein the salt of the peptide is hydrochloride.

### Claim 6 (depends on 5)

The crystalline salt according to claim 5, wherein the hydrochloride salt of the peptide has a purity of at least 98.5% as determined by HPLC.

### Claim 7

A crystalline acetate salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) having an XRPD pattern comprising one or more peaks selected from 9.08±0.2 degrees 2θ, 9.52±0.2 degrees 2θ, 10.34±0.2 degrees 2θ, and/or 14.24±0.2 degrees 2θ.

### Claim 8 (depends on 7)

The crystalline acetate salt according to claim 7 having an XRPD pattern comprising a peak at 14.24±0.2 degrees 2θ.

### Claim 9 (depends on 7)

The crystalline acetate salt according to claim 7 having an XRPD pattern comprising a peak at 14.24±0.2 degrees 2θ and one or more peaks selected from 9.08±0.2 degrees 2θ, 9.52±0.2 degrees 2θ, and/or 10.34±0.2 degrees 2θ.

### Claim 10 (depends on 8)

The crystalline acetate salt according to claim 8 further comprising one or more of the following peaks: 18.23±0.2 degrees 2θ, 19.08±0.2 degrees 2θ and/or 21.31±0.2 degrees 2θ.

### Claim 11 (depends on 10)

The crystalline acetate salt according to claim 10 having an XRPD pattern comprising peaks at 14.24±0.2 degrees 2θ and 18.23±0.2 degrees 2θ.

### Claim 12 (depends on 7)

The crystalline acetate salt according to claim 7, wherein the acetate is present at a concentration of less than about 15 mole %.

### Claim 13 (depends on 12)

The crystalline acetate salt according to claim 12, wherein the acetate is present at a concentration of less than about 10 mole %.

### Claim 14 (depends on 13)

The crystalline acetate salt according to claim 13, wherein the acetate is present at a concentration of between about 4 to about 8 mol %.

### Claim 15

An acetate salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) having an acetate concentration of less than about 10 mole % and optionally a water concentration of less than about 7 mole %.

### Claim 16 (depends on 15)

The acetate salt according to claim 15, having an acetate concentration between about 4 mol % to about 8 mol % and a water concentration between about 1 mol % to about 2 mol %.

### Claim 17 (depends on 16)

The acetate salt according to claim 16 wherein the solid state form of the salt is substantially amorphous.

### Claim 18

An isolated chloride salt of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1) with a purity of at least 98.5% as determined by HPLC.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising or prepared with the crystalline peptide salt of claim 1.
